PATENT CLAIM ANALYSIS

Application Number: 16271171
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["514", "210210"]

Abstract:
Compounds of formula (I): wherein A 1 , A 2 , R a , R b , R c , R d , R 3 , R 4 , R 5  and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Claim (Index 7):
The process according to  claim 1 , wherein T represents methyl, aminomethyl, (morpholin-4-yl)methyl, (4-methylpiperazin-1-yl)methyl, 2-(morpholin-4-yl)ethyl, [2-(morpholin-4-yl)ethoxy]methyl, hydroxymethyl, [2-(dimethylamino)ethoxy]methyl, hexahydropyrazino[2, 1-c][1,4]oxazin-8 (1H)-ylmethyl, 1-oxa-6-azaspiro [3.3]hept-6-ylmethyl, 3-(morpholin-4-yl)propyl or trifluoromethyl.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 99.0
- Lexical Diversity: 1.6087
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15419228', '14797532', '14336311', '14905877', '15428493']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8268335160262777
- 35 USC 102 Novelty (BERT): 0.6228378799015636
- Combined Prediction Score: 0.8064339524138063
- Mean Citation Score: 529.189402
- Max Citation Score: 549.1958
- Similarity Product: 532.7619729654313

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test